85 related articles for article (PubMed ID: 38654040)
21. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
Hilton J; Cristea M; Postel-Vinay S; Baldini C; Voskoboynik M; Edenfield W; Shapiro GI; Cheng ML; Vuky J; Corr B; Das S; Apfel A; Xu K; Kozicki M; Ünsal-Kaçmaz K; Hammell A; Wang G; Ravindran P; Kollia G; Esposito O; Coker S; Diamond JR
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077617
[TBL] [Abstract][Full Text] [Related]
22. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.
Ianevski A; Giri AK; Aittokallio T
Nucleic Acids Res; 2022 Jul; 50(W1):W739-W743. PubMed ID: 35580060
[TBL] [Abstract][Full Text] [Related]
23. The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion.
Jermakowicz AM; Rybin MJ; Suter RK; Sarkaria JN; Zeier Z; Feng Y; Ayad NG
Sci Rep; 2021 Dec; 11(1):23370. PubMed ID: 34862404
[TBL] [Abstract][Full Text] [Related]
24. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.
Perez-Riverol Y; Bai J; Bandla C; García-Seisdedos D; Hewapathirana S; Kamatchinathan S; Kundu DJ; Prakash A; Frericks-Zipper A; Eisenacher M; Walzer M; Wang S; Brazma A; Vizcaíno JA
Nucleic Acids Res; 2022 Jan; 50(D1):D543-D552. PubMed ID: 34723319
[TBL] [Abstract][Full Text] [Related]
25. Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.
Gavai AV; Norris D; Delucca G; Tortolani D; Tokarski JS; Dodd D; O'Malley D; Zhao Y; Quesnelle C; Gill P; Vaccaro W; Huynh T; Ahuja V; Han WC; Mussari C; Harikrishnan L; Kamau M; Poss M; Sheriff S; Yan C; Marsilio F; Menard K; Wen ML; Rampulla R; Wu DR; Li J; Zhang H; Li P; Sun D; Yip H; Traeger SC; Zhang Y; Mathur A; Zhang H; Huang C; Yang Z; Ranasinghe A; Everlof G; Raghavan N; Tye CK; Wee S; Hunt JT; Vite G; Westhouse R; Lee FY
J Med Chem; 2021 Oct; 64(19):14247-14265. PubMed ID: 34543572
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.
Singh N; Miner A; Hennis L; Mittal S
Cancer Drug Resist; 2021; 4(1):17-43. PubMed ID: 34337348
[TBL] [Abstract][Full Text] [Related]
27. Drug resistance and combating drug resistance in cancer.
Wang X; Zhang H; Chen X
Cancer Drug Resist; 2019; 2(2):141-160. PubMed ID: 34322663
[TBL] [Abstract][Full Text] [Related]
28. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
29. Achieving clinical success with BET inhibitors as anti-cancer agents.
Shorstova T; Foulkes WD; Witcher M
Br J Cancer; 2021 Apr; 124(9):1478-1490. PubMed ID: 33723398
[TBL] [Abstract][Full Text] [Related]
30. FGF/FGFR signaling in health and disease.
Xie Y; Su N; Yang J; Tan Q; Huang S; Jin M; Ni Z; Zhang B; Zhang D; Luo F; Chen H; Sun X; Feng JQ; Qi H; Chen L
Signal Transduct Target Ther; 2020 Sep; 5(1):181. PubMed ID: 32879300
[TBL] [Abstract][Full Text] [Related]
31. Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis.
Ghaemmaghami AB; Mahjoubin-Tehran M; Movahedpour A; Morshedi K; Sheida A; Taghavi SP; Mirzaei H; Hamblin MR
Cell Commun Signal; 2020 Aug; 18(1):120. PubMed ID: 32746854
[TBL] [Abstract][Full Text] [Related]
32. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Vaubel RA; Tian S; Remonde D; Schroeder MA; Mladek AC; Kitange GJ; Caron A; Kollmeyer TM; Grove R; Peng S; Carlson BL; Ma DJ; Sarkar G; Evers L; Decker PA; Yan H; Dhruv HD; Berens ME; Wang Q; Marin BM; Klee EW; Califano A; LaChance DH; Eckel-Passow JE; Verhaak RG; Sulman EP; Burns TC; Meyer FB; O'Neill BP; Tran NL; Giannini C; Jenkins RB; Parney IF; Sarkaria JN
Clin Cancer Res; 2020 Mar; 26(5):1094-1104. PubMed ID: 31852831
[TBL] [Abstract][Full Text] [Related]
33. Toward understanding the origin and evolution of cellular organisms.
Kanehisa M
Protein Sci; 2019 Nov; 28(11):1947-1951. PubMed ID: 31441146
[TBL] [Abstract][Full Text] [Related]
34. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
35. The Anti-proliferative Activity of GnRH Through Downregulation of the Akt/ERK Pathways in Pancreatic Cancer.
Suo L; Chang X; Xu N; Ji H
Front Endocrinol (Lausanne); 2019; 10():370. PubMed ID: 31263453
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
37. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.
Chua V; Orloff M; Teh JL; Sugase T; Liao C; Purwin TJ; Lam BQ; Terai M; Ambrosini G; Carvajal RD; Schwartz G; Sato T; Aplin AE
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30610113
[TBL] [Abstract][Full Text] [Related]
38. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.
Kalyukina M; Yosaatmadja Y; Middleditch MJ; Patterson AV; Smaill JB; Squire CJ
ChemMedChem; 2019 Feb; 14(4):494-500. PubMed ID: 30600916
[TBL] [Abstract][Full Text] [Related]
39. Drug and disease signature integration identifies synergistic combinations in glioblastoma.
Stathias V; Jermakowicz AM; Maloof ME; Forlin M; Walters W; Suter RK; Durante MA; Williams SL; Harbour JW; Volmar CH; Lyons NJ; Wahlestedt C; Graham RM; Ivan ME; Komotar RJ; Sarkaria JN; Subramanian A; Golub TR; Schürer SC; Ayad NG
Nat Commun; 2018 Dec; 9(1):5315. PubMed ID: 30552330
[TBL] [Abstract][Full Text] [Related]
40. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting.
Farrell B; Breeze AL
Biochem Soc Trans; 2018 Dec; 46(6):1753-1770. PubMed ID: 30545934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
